Zacks Research Has Negative Outlook of AGIO Q1 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at Zacks Research dropped their Q1 2025 EPS estimates for shares of Agios Pharmaceuticals in a note issued to investors on Thursday, March 6th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings per share of ($1.81) for the quarter, down from their prior estimate of ($1.64). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q2 2025 earnings at ($1.75) EPS, Q3 2025 earnings at ($1.79) EPS, Q4 2025 earnings at ($2.02) EPS, FY2025 earnings at ($7.37) EPS, Q1 2026 earnings at ($1.76) EPS, Q2 2026 earnings at ($1.65) EPS, Q3 2026 earnings at ($1.59) EPS, Q4 2026 earnings at ($1.42) EPS and FY2026 earnings at ($6.42) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.

A number of other equities research analysts have also recently issued reports on the company. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. HC Wainwright started coverage on shares of Agios Pharmaceuticals in a research report on Monday, February 24th. They set a “buy” rating and a $58.00 target price for the company. Finally, Royal Bank of Canada raised their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $56.57.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $32.38 on Monday. The business’s 50-day simple moving average is $33.80 and its 200-day simple moving average is $42.28. Agios Pharmaceuticals has a 52 week low of $27.14 and a 52 week high of $62.58. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of 2.86 and a beta of 0.90.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the sale, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after buying an additional 85,339 shares in the last quarter. State Street Corp lifted its holdings in shares of Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock worth $103,586,000 after acquiring an additional 216,484 shares during the period. Erste Asset Management GmbH acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at about $97,199,000. Jefferies Financial Group Inc. acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at about $49,290,000. Finally, Geode Capital Management LLC increased its stake in Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after acquiring an additional 6,101 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.